Aptamer Group to announce full year 2025 results on 14 October

Aptamer Group plc (LON:APTA), the leading developer of next-generation synthetic binders delivering innovation to the life science industry, will announce its full year results for the year ended 30 June 2025 on Tuesday, 14 October 2025 and hold the following analyst briefing and investor presentation.

Analyst briefing

An online briefing for analysts will be hosted by Dr Arron Tolley, Chief Executive Officer and Andrew Rapson, Chief Financial Officer, at 9.30 am on Tuesday, 14 October 2025, to review the full year results. Analysts wishing to attend should contact Sarah Hollins at Northstar Communications at sarah@northstarcommunications.co.uk.

Share on:

You might also enjoy reading Aptamer signs therapeutic development deal with Invizius

Written by: Amilia Stone

Latest Company News

Aptamer reports 27% revenue growth and signs multiple licensing deals in H1 FY26

January 7, 2026

Aptamer Group reported unaudited revenue of £0.83 million for the six months to 31 December 2025, a 27% increase year on year, supported by strong fee-for-service demand and the signing of multiple licensing agreements.

Aptamer Group signs first licensing deal with Twist Bioscience

December 16, 2025

Aptamer Group has entered into its first licensing agreement with Twist Bioscience, granting a non-exclusive licence for the use of an Optimer® binder in hot-start PCR and next-generation sequencing products.

Aptamer Group AGM statement highlights contract wins and growing order book

November 27, 2025

Aptamer Group is holding its AGM today in York, where the Chairman will outline continued commercial progress, recent contract wins with major pharmaceutical companies, and an FY26 order book of £1.95 million.

Aptamer Group secures £192k contracts with global pharma, boosting FY26 order book to £1.95m

November 14, 2025

Aptamer Group announced two new contracts worth £192,000, including a fourth engagement with a top five global pharmaceutical company and a new deal targeting acute myeloid leukaemia.

Aptamer Group reports strong FY2025 growth and expands Optimer® portfolio

November 3, 2025

Aptamer Group delivered strong progress in FY2025, achieving a 40% revenue increase and expanding its portfolio of licensable Optimer® assets from four to eleven.

Aptamer Group delivers 40% revenue growth and expands licensing portfolio

October 14, 2025

Aptamer Group has announced its full-year results for the twelve months ended 30 June 2025, delivering a 40% increase in revenue to £1.2 million and expanding its Optimer® licensing portfolio from four to eleven assets.